Non-alcoholic Steatohepatitis Biomarkers Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET OVERVIEW

Non-alcoholic steatohepatitis (NASH) is a type of severe fatty liver disease that is non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition caused due to fat accumulation in the liver and the continuous fat deposition may cause liver inflammation and injury that is known as NASH. NASH can result in scarring of the liver, which is a potentially life-threatening condition known as cirrhosis. The symptoms includes easy bleeding and bruising, itchy skin, jaundice, loss of appetite, nausea, and many more. NASH is more prevalent in patients who are overweight or obese including diabetic, people with elevated cholesterol, inadequate nutrition, polycystic ovary syndrome, and hypothyroidism. Various innovative diagnostic tools are used for accurate diagnosis of the non-alcoholic steatohepatitis condition such as liver biopsy. However, due to high cost of this procedure, various companies have introduced biomarkers as a diagnostic tool for NASH patients such as serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, gene biomarkers, and oxidative stress biomarkers.

MARKET SCOPE

The

"Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis to 2031"

is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the non-alcoholic steatohepatitis biomarkers market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading non-alcoholic steatohepatitis biomarkers market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

•  Based on type, the global non-alcoholic steatohepatitis biomarkers market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers and others.
  
•  On the basis of application, the market is segmented into pharmaceutical & CRO industry, hospitals, diagnostic labs and academic research institutes.
  

MARKET DYNAMICS

Drivers

•   Rising prevalence of non-alcoholic steatohepatitis (NASH), growing patient pool suffering from diabetes and obesity is driving the non-alcoholic steatohepatitis biomarkers market.
  
•   Increasing patient awareness, growing need for appropriate diagnostic methods and growing demand for noninvasive diagnostic instruments boosts the market growth.
  
•   Growing technological advancements, increasing research and development activities and high prevalence of non-alcoholic fatty liver disease (NAFLD) fuel the market growth.
  
•   Rising advancements in the healthcare infrastructure in developing economies propel the market growth.
  

Restraints

•   Side effects of NASH therapeutics.
  
•   Lack of advanced diagnostic testing for NAFLD.
  

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The non-alcoholic steatohepatitis biomarkers market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the non-alcoholic steatohepatitis biomarkers market in these regions.

IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET

COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The outbreak of novel coronavirus pandemic impacted the growth of the market. It has created major roadblocks for companies which are operating in the non-alcoholic steatohepatitis (NASH) biomarkers market. Due to supply chain disruptions, business shutdown, country-wise lockdown the marketers faced a challenging situation. Companies should now focus on effective business strategies formulation and product diversification in order to overcome the challenges that has aroused during the global pandemic.

MARKET PLAYERS

The report covers key developments in the non-alcoholic steatohepatitis biomarkers market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from non-alcoholic steatohepatitis biomarkers market are anticipated to have lucrative growth opportunities in the future with the rising demand for non-alcoholic steatohepatitis biomarkers in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the non-alcoholic steatohepatitis biomarkers market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

•  BioPredictive
  
•  Cisbio
  
•  Allergan
  
•  NGM Biopharmaceuticals
  
•  AstraZeneca
  
•  Novartis AG
  
•  Novo Nordisk A/S
  
•  Pfizer, Inc.
  
•  Siemens Healthineers
  
•  Genfit
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Non-alcoholic Steatohepatitis Biomarkers Report Scope